Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA NephropathyChronic Disease, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, IgA glomerulonephritis, Male Urogenital Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, autoimmune disease, chronic renal failure syndrome, glomerulonephritis, immune system disorder, kidney disorder, kidney failure, nephritis, urinary system disorderRecruitingPhase 32026-10-05NCT04557462

1 results · Page 1 of 1

Swipe the table sideways for more columns.

OrganizationsLinked trials
Novartis Pharmaceuticals432

16 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sitesCityCountryLinked trials
AZ Kidney Dise and Hypertension CtrGlendaleUnited States1
Brigham and Womens Hosp Harvard Med SchoolBostonUnited States5
CaRe ResearchChubbuckUnited States2
Clin Rsrch Consult a JCCT CompanyKansas CityUnited States2
Col Uni Med Center New York PresbyNew YorkUnited States6
Dallas Renal GroupDallasUnited States9
DaVita Clinical ResearchLas VegasUnited States3
Johns Hopkins HospitalBaltimoreUnited States135
Kaiser PermanenteSan DiegoUnited States2
Mayo Clinic RochesterRochesterUnited States133
Nep Assoc of Northern IllinoisHinsdaleUnited States2
Nephrology Associates PANewarkUnited States2
New Jersey Kidney CareJersey CityUnited States2
North America Research InstituteSan DimasUnited States11
Prolato Clinical Research CenterHoustonUnited States22
University of Colorado AnschutzAuroraUnited States30